X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TEVA PHARMA (Israel) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
TEVA PHARMA
Dec-13
AUROBINDO PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8952,840-   
Low Rs6222,467-   
Sales per share (Unadj.) Rs254.61,629.9-  
Earnings per share (Unadj.) Rs39.3101.8-  
Cash flow per share (Unadj.) Rs46.6233.6-  
Dividends per share (Unadj.) Rs2.5089.13-  
Dividend yield (eoy) %0.33.4 9.8%  
Book value per share (Unadj.) Rs160.01,810.5-  
Shares outstanding (eoy) m585.88848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 183.0%   
Avg P/E ratio x19.326.1 74.1%  
P/CF ratio (eoy) x16.311.4 143.3%  
Price / Book Value ratio x4.71.5 323.5%  
Dividend payout %6.487.5 7.3%   
Avg Mkt Cap Rs m444,3902,250,219 19.7%   
No. of employees `00014.044.9 31.1%   
Total wages/salary Rs m17,6780-   
Avg. sales/employee Rs Th10,667.830,752.4 34.7%   
Avg. wages/employee Rs Th1,264.30-   
Avg. net profit/employee Rs Th1,645.81,921.1 85.7%   
INCOME DATA
Net Sales Rs m149,1571,382,165 10.8%  
Other income Rs m1,1590-   
Total revenues Rs m150,3161,382,165 10.9%   
Gross profit Rs m34,343378,507 9.1%  
Depreciation Rs m4,276111,722 3.8%   
Interest Rs m66727,148 2.5%   
Profit before tax Rs m30,558239,637 12.8%   
Minority Interest Rs m501,089 4.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-157,308 0.0%   
Tax Rs m7,597-2,926 -259.6%   
Profit after tax Rs m23,01286,343 26.7%  
Gross profit margin %23.027.4 84.1%  
Effective tax rate %24.9-1.2 -2,036.1%   
Net profit margin %15.46.2 247.0%  
BALANCE SHEET DATA
Current assets Rs m92,062933,509 9.9%   
Current liabilities Rs m66,223814,099 8.1%   
Net working cap to sales %17.38.6 200.5%  
Current ratio x1.41.1 121.2%  
Inventory Days Days10691 116.7%  
Debtors Days Days6896 70.6%  
Net fixed assets Rs m62,919451,445 13.9%   
Share capital Rs m5863,402 17.2%   
"Free" reserves Rs m93,1330-   
Net worth Rs m93,7191,535,323 6.1%   
Long term debt Rs m1,814706,731 0.3%   
Total assets Rs m162,4943,158,689 5.1%  
Interest coverage x46.89.8 476.2%   
Debt to equity ratio x00.5 4.2%  
Sales to assets ratio x0.90.4 209.8%   
Return on assets %14.63.6 405.6%  
Return on equity %24.65.6 436.6%  
Return on capital %32.74.9 663.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m45,6130-   
CASH FLOW
From Operations Rs m32,786220,245 14.9%  
From Investments Rs m-17,870-78,042 22.9%  
From Financial Activity Rs m-19,153-264,199 7.2%  
Net Cashflow Rs m-4,239-121,996 3.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare AUROBINDO PHARMA With: SUVEN LIFE  PANACEA BIOTECH  J.B.CHEMICALS  DR. REDDYS LAB  WOCKHARDT LTD.  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 18, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS